SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces Investigation Into Possible Breaches Of Fiduciary Duty By The Board Of DUSA Pharmaceuticals Inc. In Connection With The Sale Of The Company To Sun Pharmaceutical Industries Limited

Levi & Korsinsky is investigating the Board of Directors of DUSA Pharmaceuticals Inc. (“DUSA” or the “Company”) (Nasdaq: DUSA) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to Sun Pharmaceutical Industries Limited (Reuters: SUN.BO).

Click here to learn more about the investigation: http://zlk.9nl.com/dusa-pharmaceuticals-dusa/, or call: 877-363-5972. There is no cost or obligation to you.

Under the terms of the transaction, DUSA shareholders will receive $8 in cash for each share of DUSA stock they own, for a total transaction value of approximately $230 million. The investigation concerns whether the DUSA Board of Directors breached their fiduciary duties to DUSA stockholders by failing to adequately shop the Company before entering into this transaction and whether Sun Pharmaceutical Industries Limited is underpaying for DUSA shares, thus unlawfully harming DUSA stockholders. In particular, at least one analyst set a price target for DUSA stock at $9.50 per share.

If you own common stock in DUSA and wish to obtain additional information, please contact Joseph E. Levi, Esq. either via email at jlevi@zlk.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit http://zlk.9nl.com/dusa-pharmaceuticals-dusa/.

Levi & Korsinsky is a national firm with offices in New York and Washington D.C. The firm has extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. The attorneys at Levi & Korsinsky have been appointed by numerous courts throughout the country to serve as lead counsel on behalf of shareholders in major securities lawsuits and have successfully recovered multimillion-dollar damages awards on behalf of investors. For more information, please feel free to contact any of the attorneys listed below. Attorney advertising. Prior results do not guarantee similar outcomes.

Copyright Business Wire 2010

If you liked this article you might like

5 Stocks Under $10 Soaring Higher

5 Stocks Under $10 Soaring Higher

DUSA's CEO Discusses Q2 2012 Results - Earnings Call Transcript

DUSA's CEO Discusses Q2 2012 Results - Earnings Call Transcript

8 Stocks Under $10 Ripping Higher

8 Stocks Under $10 Ripping Higher

DUSA Pharmaceuticals Inc. Stock Upgraded (DUSA)

DUSA Pharmaceuticals Inc. Stock Upgraded (DUSA)

DUSA Pharmaceuticals Inc. Stock Downgraded (DUSA)

DUSA Pharmaceuticals Inc. Stock Downgraded (DUSA)